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EFFECT OF EPA ETHYL ESTER ON FATTY ACID PROFILE IN HEMODIALYSIS
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Background: Large amounts of n-3 polyunsaturated fatty acids are known
to lower the risk of cardiovascular events (CVE). Serum eicosapentaenoic
acid (EPA) / arachidonic acid (AA) ratio may potentially be a predictor of
CVE which is the most common cause of death in hemodialysis (HD)
patients. Therefore, we estimated the effect of EPA ethyl ester on fatty acid
proﬁle in HD patients.
Subjects & Methods: Fatty acid proﬁle and high sensitivity CRP (hs-CRP)
were measured in 131 patients receiving maintenance HD. Among these,
64 patients (F:M¼25:39) with both low EPA/AA ratio (%0.4) and negative
CRP were enrolled in this randomized study (Group A, EPA administrated
group, n¼30; Group B, EPA non-administrated group, n¼34). The mean
age of the patients was 66.5 7 11.9 years old and the duration of HD was
8.4 7 7.9 years. The serum levels of EPA, AA, docosahexaenoic acid (DHA),
and dihomogammalinolenic acid (DHL-A) were measured by gas
chromatography (SRL, Tokyo, Japan).
Results: The mean levels of EPA/AA ratio, DHA/AA ratio, DHL-A, non HDL-C
and GNRI (Geriatric Nutritional Risk Index) were 0.2870.13, 0.6270.15,
22.778.4 mg/ml, 112.2731.0 mg/dl and 93.675.5, respectively. After one
month of treatment with EPA in group A, EPA/AA ratio was signiﬁcantly
increased (0.3070.15 vs. 0.9570.45, po0.0001) and DHL-A signiﬁcantly
decreased (22.777.4 vs. 15.776.8, p¼ 0.0003), but DHA/AA ratio, serum
non HDL-C and phosphate levels did not change. EPA/AA ratio was
signiﬁcantly higher and DHL-A lower in group A compared with group B
after one month of the start of study.
Conclusions: Medication of EPA for one month increases EPA/AA ratio, and
decreases DHL-A level without the change of serum phosphate level in HD
patients with low EPA/AA ratio.
http://dx.doi.org/10.1016/j.krcp.2012.04.38360
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The best biomarker of Vitamin D status is calcifediol [25(OH)D]. We
investigated the relationship between serum calcifediol levels and vertebral
fractures (VF), vascular calciﬁcations (VC) and mortality in hemodialysis
patients. Within a multicenter, cross-sectional study in 18 hospital based
dialysis centers in Italy, we included 387 hemodialysis patients (143 F, 37% ;
244 M, 63%), mean age 64714 (SD) years, median dialytic age 49 months,
BMI 257 4 Kg/m2. We determined total 25(OH)D using the LIASONs 25 OH
Vitamin D kit (DiaSorin Inc., Stillwater MN, USA). We evaluated VF with a
computerized analysis of scanned L-L vertebral X-rays (T4 to L5). Reduction of
4 20% of vertebral body height was considered a VF, while reductions
between 15% and 20% were considered borderline fractures (BF). Fracture
severity was estimated as mild, moderate or severe (reduction: 20–25%, 25–
40% or 440%, respectively). VC assessments were also centralized.
Witteman’s method (Lancet, 1994) was used for blinded assessments in
duplicate. VC were quantiﬁed by measuring the length of calciﬁc deposits
along the anterior and posterior wall of the aorta (mild 0.1-5 cm, moderate
5.1-10 cm and severe 410 cm). We also evaluated the presence or absence of
calciﬁcations of the iliac arteries in the same radiograph (mild 0.1-3 cm,
moderate 3.1-5 cm and severe 45cm). Any differences in VC were resolved
by consensus. Follow up was 2.770.5 years.
Bone markers were: Ca 9.1570.68 mg/dl, P 4.87 1.28 mg/dl, median ALP
83 U/L and median PTH 244 pg/ml. We found a median 25(OH)D level of 28.9
ng/ml. Nine ( 2.3%) patients had vitamin D deﬁciency (o10 ng/ml), 198
(51.2%) patients had vitamin D insufﬁciency (between 10-29.9 ng/ml) and 180(46.5%) patients had normal levels ( 430 ng/ml). We found that 55% of
patients had VF and 30.9% of patients had BF. Prevalence of VC was 80.6%
(mild 20.1%, moderate 30.8%, severe 29.7%) in the aorta and 55,1% in the iliac
arteries. Males had more VF than Females (60% versus 48%, P¼0.019). No
associations were found between VF and biochemical parameters including
calcifediol levels (p¼0.662), while we found an association between low
calcifediol levels and a higher prevalence of severe aortic calciﬁcations (36.8
vs 28.2, p¼0.0044). Furthermore, we found a OR 1.85 (1.04-3.29 CI,
p¼0.0367) for Aortic Calciﬁcation in patients with calcifediol levels lower
than the median value of 29 ng/ml. During follow-up (2.770.5 years)
mortality was of 19.9%. No association was found between mortality and
calcifediol levels (p¼0.5394). In conclusion, despite good control of bone and
mineral metabolism parameters, hemodialysis patients showed high
prevalence of VF and VC. Our study suggests that high calcifediol levels could
be protective against progression of severe aortic calciﬁcation
http://dx.doi.org/10.1016/j.krcp.2012.04.38461
KETO-ANALOGUES IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE
PATIENTS: REVIEW OF OLD AND NEW DATA
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Recently revealed high prevalence of Chronic Kidney Disease (CKD)
raises concerns all over the world; evidence based strategies to delay
progression were set up. Dietary approach is largely mentioned, but strong
evidence is lacking.
The reduced dietary protein intake has been reported for more than a
century to improve uremic symptoms and even to postpone the initiation
of renal replacement therapy (RRT); however, the nutritional intervention
in uremia is still under debate.
Different dietary protein regimens have been proposed for the CKD
patients: (1) conventional low protein diet (LPD), with 0.6 g/kg per day;
(2) very low protein diet (0.3 g/kg per day) supplemented with essential
amino acids or (3) very low protein diet (0.3 g/kg per day) supplemented with
an isomolar mixture of essential amino acids and nitrogen-free keto-
analogues (SVLPD).
Available data support SVLPD to be effective in ameliorating nitrogen waste
products retention, acid-base and calcium-phosphorus metabolism
disturbances and insulin-resistance and in delaying the RRT initiation, with no
deleterious effect on the nutritional status in CKD patients.More recent studies
report that SVLPD could also slow down the rate of decline in renal function,
preserving the nutritional status and associating better outcome after the start
of RRT.
The possible delay of RRT initiation through nutrition could have major
impact on patients’ quality of life. On the other hand, postponing RRT could
have also a serious economic impact, particularly important in countries where
the dialysis facilities still do not meet the needs. The nutritional intervention,
particularly the SVLPD could be a new link in the RRT integrated care model.
However, a careful selection of motivated patients who could beneﬁt from
such a diet, close nutritional monitoring and dietary counseling are highly
required.
http://dx.doi.org/10.1016/j.krcp.2012.04.38562
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Introduction: The nutritional status of the ESRD patients is a crucial issue in
the disease progression, thats the reason why the patient nutritional
education is so important.Our objective is to evaluate the change in the
nutritional status in a group of ESRD patients after a personalized
nutritional education program. Method Longitudinal case study of 103
patients who took part in a nutritional educational program over six
months (personalized diet, education and oral supplementation).
Results: See below Table 1.
